Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting

American Journal of Therapeutics

Volumn 13, Issue 6, 2006, Pages 502-506

  Ollendorf, Daniel A ^a   Lidsky, Loren ^a  

^a PharMetrics Inc   (United States)

Author keywords

Antibodies; Costs and cost analysis; Crohn's Disease; Monoclonal; Pricing

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL PRACTICE; COST OF ILLNESS; CROHN DISEASE; DRUG COST; DRUG INFUSION; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG COSTS; DRUG UTILIZATION; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INSURANCE CLAIM REVIEW; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 33751360290     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000245223.43783.45     Document Type: Article

References (16)

1. Crohn's Disease. National Digestive Diseases Information Clearinghouse (NDDIC). National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), National Institutes of Health. NIH Publication No. 03-3410, January 2003.
2. Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess. 2003;7:1-67.
3. Loftus EV, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival. Gastroenterology. 1998;114:1161-1168.
4. Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's Disease: A payor perspective. Am J Gastroenterol. 2000;95:1955-1960.
5. REMICADE [package insert]. Malvern, PA: Centocor, Inc., 2004.
6. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric moncolonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
7. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
8. D'Haens G, van Deventer S, van Hogezand R, et al. Endoscopic and histological healing with infliximab antitumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999;116:1029-1034.
9. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-96.
10. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002;35:151-156.
11. National Institute for Clinical Exellence. Guidance on the use of infliximab for Crohn's disease. Available at: http://www.nice.org.uk/pdf/ CrohnsWelshEnglishA4summary.pdf. May 2, 2002; Accessed August 24, 2004.
12. Master Drug Database (MDDB). Indianapolis, Facts and Comparisons, Inc. Accessed March 28, 2006.
13. GI Health.com. All About Remicade (Infliximab). Available at: http://www.gihealth.com/html/education/drugs/remicade.html. Accessed August 24, 2004.
14. Infliximab (Remicade). FamilyPracticeNotebook.com. Available at: http://www.fpnotebook.com/RHE104.htm. Accessed August 24, 2004.
15. Marshall JK. Funding the new biologics - CCOHTA report on the cost effectiveness of infliximab for Crohn's disease: Pearls and pitfalls. Can J Gastro. 2002;16:877-879.
16. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalization, surgeries and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869.